(2)Commission Implementing Regulation (EU) 2020/2007note extended the approval period of the active substance spirotetramat from 30 April 2024 until 31 July 2024, spinetoram and L-ascorbic acid from 30 June 2024 until 30 September 2024 and flubendiamide from 31 August 2024 until 30 November 2024. The extensions were necessary because Commission Implementing Regulation (EU) 2020/1740note advanced the date of submission of the dossiers in support of the renewal of approval by 3 months. Therefore, it was necessary to maintain the date of the dossier submission as required under Commission Implementing Regulation (EU) No 844/2012note, while giving applicants time to prepare and submit the dossiers in the required format.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.